Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, shared a post on X:
“persevERA (giredestrant+palbo vs AI+palbo in 1L ER+ MBC) didn’t meet its primary endpt. Data from PARSIFAL (fulv + palbo=AI + palbo) suggested having a better endocrine partner w/cdk 4/6i in endocrine-sensitive dz may not matter. Will need to see what SERENA-4 shows.”
Other posts featuring Sara Tolaney on OncoDaily.